

a LANGE clinical manual

Internal Medicine

Diagnosis and Therapy

Department of Medicine
University of Texas Health Science Center
San Antonio

2nd
Edition



一九九三年九月十三日

a LANGE clinical manual

Internal Medicine

Diagnosis and Therapy

Department of Medicine
University of Texas Health Science Center
San Antonio

2nd
Edition

Edited by

Jay H. Stein, MD
Dan F. Parman Distinguished Chair in Medicine
Professor and Chairman
Department of Medicine
University of Texas Health Science Center
San Antonio, Texas



APPLETON & LANGE
Norwalk, Connecticut/San Mateo, California

0-8385-1299-2

Notice: Our knowledge in clinical sciences is constantly changing. As new information becomes available, changes in treatment and in the use of drugs become necessary. The authors and the publisher of this volume have taken care to make certain that the doses of drugs and schedules of treatment are correct and compatible with the standards generally accepted at the time of publication. The reader is advised to consult carefully the instruction and information material included in the package insert of each drug or therapeutic agent before administration. This advice is especially important when using new or infrequently used drugs.



Copyright © 1991 by Appleton & Lange
A Publishing Division of Prentice Hall

First Edition, Copyright © 1988 by Appleton & Lange
A Publishing Division of Prentice Hall, Inc.

All rights reserved. This book, or any parts thereof, may not be used or reproduced in any manner without written permission. For information, address Appleton & Lange, 25 Van Zant Street, East Norwalk, Connecticut 06855.

91 92 93 94 95 / 10 9 8 7 6 5 4 3 2 1

Prentice Hall International (UK) Limited, London
Prentice Hall of Australia Pty Ltd., Sydney
Prentice Hall Canada, Inc., Toronto
Prentice Hall Hispanoamericana, S.A., Mexico
Prentice Hall of India Private Limited, New Delhi
Prentice Hall of Japan, Inc., Tokyo
Simon & Schuster Asia (Pte.) Ltd., Singapore
Editora Prentice Hall do Brasil Ltda., Rio de Janeiro
Prentice Hall, Englewood Cliffs, New Jersey

ISBN 0-8385-1299-2
ISSN 0897-6309

Production Editor: Christine Langan
Design: Steve Byrum

PRINTED IN THE UNITED STATES OF AMERICA

Contributors

Ralph A. DeFronzo, MD

[Metabolic Disorders]

Professor of Medicine and Chief, Diabetes Division, Department of Medicine, University of Texas Health Science Center, San Antonio.

Louis J. Dell'Italia, MD

[Diseases of the Heart]

Assistant Professor of Medicine, Cardiovascular Disease Division, Department of Medicine, University of Alabama, Birmingham.

Richard L. De Villez, MD

[Skin Diseases]

Professor of Medicine, Dermatology Division, Department of Medicine, University of Texas Health Science Center, San Antonio.

James F. Dunn, MD

[Endocrine Disorders]

Assistant Professor of Medicine and Assistant Program Director, Clinical Research Unit, Endocrinology Division, Department of Medicine, University of Texas Health Science Center, San Antonio.

Gregory L. Freeman, MD

[Diseases of the Heart]

Associate Professor of Medicine, Cardiology Division, Department of Medicine, University of Texas Health Science Center, San Antonio.

Bonnie B. Furner, MD

[Skin Diseases]

Assistant Professor of Medicine, Dermatology Division, Department of Medicine, University of Texas Health Science Center, San Antonio.

Thomas C. Hardin, PharmD, FCCP

[General Aspects of Drug Therapy; Hospital Orders]

Clinical Associate Professor of Medicine and Pharmacology, Pharmacology Division, Department of Medicine, University of Texas Health Science Center, San Antonio.

Gary D. Harris, MD**[Pulmonary Diseases]**

Associate Professor of Medicine, Pulmonary Division, Department of Medicine, University of Texas Health Science Center, San Antonio.

Claudia E. Hura, MD**[Renal and Electrolyte Disorders; Drug Dosages for Patients with Renal Failure]**

Assistant Professor of Medicine, Nephrology Division, Department of Medicine, University of Texas Health Science Center, San Antonio.

Michael S. Katz, MD**[Endocrine Disorders]**

Associate Professor and Head, Geriatrics and Gerontology Division, Department of Medicine, University of Texas Health Science Center, San Antonio. Director, Geriatric Research, Education and Clinical Center, and Associate Chief of Staff for Extended Care, Audie L. Murphy Memorial Veterans Hospital, San Antonio.

Valerie A. Lawrence, MD**[General Aspects of Drug Therapy; Hospital Orders]**

Assistant Professor of Medicine, General Medicine Division, Department of Medicine, University of Texas Health Science Center, San Antonio. Staff Physician, Audie L. Murphy Memorial Veterans Hospital, San Antonio.

Jonathan A. Leighton, MD**[Emergencies]**

Fellow, Gastroenterology, Gastroenterology and Nutrition Division, Department of Medicine, University of Texas Health Science Center, San Antonio.

Shirley P. Levine, MD**[Hematologic Disorders]**

Associate Professor of Medicine, Hematology Division, Department of Medicine, University of Texas Health Science Center, San Antonio.

John P. Mulrow, MD**[Diseases of the Heart]**

Assistant Professor of Medicine, Medical Director of Cardiac Transplantation, Cardiology Division, Department of Medicine, University of Texas Health Science Center, San Antonio.

I. Jon Russell, MD, PhD**[Rheumatologic and Musculoskeletal Disorders]**

Associate Professor of Medicine, Clinical Immunology Division, Department of Medicine, University of Texas Health Science Center, San Antonio.

Alexander M.M. Shepherd, MD, PhD**[Hypertension]**

Associate Professor of Medicine and Pharmacology and Chief, Clinical Pharmacology Division, Department of Medicine, University of Texas Health Science Center, San Antonio.

David G. Sherman, MD**[Neurologic Diseases]**

Professor and Chief, Neurology Division, Department of Medicine, University of Texas Health Science Center, San Antonio.

Jean A. Smith, MD

[Infectious Diseases]

Assistant Professor of Medicine, Infectious Diseases Division, Department of Medicine, University of Texas Health Science Center, San Antonio.

David L. Stump, MD

[Gastrointestinal, Liver, and Pancreatic Diseases]

Assistant Professor of Medicine, Gastroenterology and Nutrition Division, Department of Medicine, University of Texas Health Science Center, San Antonio. Chief, Gastroenterology, Audie L. Murphy Memorial Veterans Hospital, San Antonio.

Knox H. Todd, MD

[Emergencies]

Assistant Professor, General Medicine Division, Department of Medicine, University of Texas Health Science Center, San Antonio.

Geoffrey R. Weiss, MD

[Oncology]

Associate Professor of Medicine, Oncology Division, Department of Medicine, University of Texas Health Science Center, San Antonio.

Elliot Weser, MD, FACP

[Nutritional Assessment and Therapy]

Professor of Medicine, Gastroenterology and Nutrition Division, Department of Medicine, University of Texas Health Science Center, San Antonio. Chief, Medicine Service, Audie L. Murphy Memorial Veterans Hospital, San Antonio.

A. John Yates, MD

[Metabolic Disorders]

Assistant Professor, Endocrinology Division, Department of Medicine, University of Texas Health Science Center, San Antonio.

Eleanor A. Young, PhD, RD/LD

[Nutritional Assessment and Therapy]

Professor of Medicine, Gastroenterology and Nutrition Division, Department of Medicine, University of Texas Health Science Center, San Antonio.

Preface

PURPOSE

The goal of the second edition of this manual is the same as that for the first edition—to provide a practical, portable source of essential information needed for the effective management of the most important medical syndromes and diseases. As we embarked on preparation of the second edition, we were very encouraged by the response to the first edition. Features of the first edition that won high marks were the numerous practical tables, the detailed information on diagnosis as well as treatment, and the inclusion of some important diseases and syndromes not found in other similar manuals. These features have been retained and, whenever possible, improved upon. We trust that medical students, house staff, and practicing physicians will continue to find the manual a "constant" pocket companion for the betterment of patient care.

ORGANIZATION AND SCOPE

Like the first edition, the second edition groups diseases and syndromes into chapters by medical subspecialty, with the exception of the first chapter, General Aspects of Drug Therapy. The last chapter is devoted to medical emergencies. All material in the first edition was carefully reviewed for necessary updating on the most current techniques in clinical diagnosis and therapy. There is increased space devoted to acquired immune deficiency syndrome (AIDS), more detailed sections on the management of coronary artery disease and diabetes, and an extensive update of antibiotic therapy, to mention just a few enhancements.

OTHER USEFUL FEATURES

- The convenient outline format and selective use of boldface type afford quick, easy access to key aspects of patient assessment and management.
- Basic summaries of a disease's pathophysiology are provided when important for the understanding of the rationale behind the approach to diagnosis and therapy.
- Precise guidelines on approach to diagnosis and therapy. For indicated drug therapy, details on dosage and administration are given.
- Two appendices: Hospital Orders; Drug Dosages for Patients with Renal Failure.
- Table on drugs and procedures for advanced cardiac life support on inside front cover.
- References at the end of each chapter, listing recent clinical studies and reviews.

The editor welcomes suggestions and comments about any aspects of this manual. Letters should be addressed to:

Jay H. Stein, MD
Department of
Medicine
University of Texas
Health Sciences
Center
7703 Floyd Curl Dr.
San Antonio, TX
78284

Contents

Cardiovascular Emergency Drugs	<i>Inside front cover</i>
Contributors	ix
Preface	xiii
1. General Aspects of Drug Therapy	1
<i>Valerie A. Lawrence, MD, and Thomas C. Hardin, PharmD, FCCP</i>	
<i>Basic Principles of Drug Therapy 1 / Pharmacokinetic Monitoring 1 / Drug Interaction 1 / Drug Therapy and Renal Function 2 / Drug Therapy and Hepatic Function 5 / Drug Therapy and the Elderly 6 / Pain Management With Analgesic Drugs 6 / Sedative-Hypnotics and Anxiolytics 9 / Psychoactive Drugs 13</i>	
2. Diseases of the Heart	18
<i>Gregory L. Freeman, MD, John P. Mulrow, MD, and Louis J. Dell'Italia, MD</i>	
<i>Congestive Heart Failure 18 / Arrhythmias 32 / Coronary Artery Disease 53 / Acute Myocardial Infarction 61 / Valvular Heart Disease 74 / Aortic Stenosis 75 / Chronic Aortic Regurgitation 77 / Acute Aortic Regurgitation 78 / Mitral Stenosis 79 / Mitral Regurgitation 81 / Acute Mitral Regurgitation 82 / Tricuspid Stenosis 83 / Tricuspid Regurgitation 84 / Multivalvular Disease 84 / Pericardial Disease 85 / Acute Pericarditis 85 / Pericardial Tamponade 86 / Constrictive Pericarditis 88</i>	
3. Pulmonary Diseases	90
<i>Gary D. Harris, MD</i>	
<i>Common Pulmonary Symptoms 90 / Dyspnea 90 / Cough 93 / Hemoptysis 95 / Chest Pain 98 / Assessment of Pulmonary Function 99 / Pulmonary Diseases 99 /</i>	

Asthma 99 / Chronic Obstructive Pulmonary Disease (COPD) 104 / Pulmonary Embolism 107 / Pleural Effusion 111 / Interstitial Lung Disease 113 / Lung Cancer 115 / Aspiration Syndromes 119 / Lung Abscess 120 / Acute Respiratory Failure 121

4. Renal and Electrolyte Disorders 130
Claudia E. Hura, MD

Renal Syndromes 130 / Hematuria 130 / Proteinuria 132 / Nephrotic Syndrome 134 / Acute Renal Failure 136 / Chronic Renal Failure 139 / Nephrolithiasis 143 / Renal Diseases 145 / Glomerular Diseases 145 / Interstitial Diseases 151 / Urinary Tract Obstruction 152 / Disorders of Water Metabolism 153 / Hyponatremia 153 / Hypernatremia 156 / Edematous States and Diuretics 157 / Disorders of Potassium Balance 159 / Hypokalemia 160 / Hyperkalemia 162 / Disorders of Acid-Base Balance 164 / Metabolic Acidosis 165 / Metabolic Alkalosis 167 / Respiratory Acidosis 168 / Respiratory Alkalosis 168 / Mixed Acid-Base Disorders 168

5. Hypertension 170
Alexander M. M. Shepherd, MD, PhD

Primary (Essential) Hypertension 170 / Drugs Used to Treat Primary Hypertension 175 / Diuretics 175 / Adrenergic Inhibitors 177 / Alpha-Adrenergic Blocking Agents 179 / Vasodilators 179 / Clonidine 180 / Methyldopa 181 / Complicated Hypertension 181 / Malignant Hypertension 181 / Hypertensive Encephalopathy 181 / Systolic Hypertension 182 / Secondary Hypertension 183 / Hypertension Secondary to Chronic Renal Disease 183 / Renovascular Hypertension 184 / Hypertension Secondary to Coarctation of the Aorta 185 / Hypertension Secondary to Primary Aldosteronism 185 / Pheochromocytoma 185 / Hypertension in the Elderly 186 / Hypertension in Pregnancy 187

6. Gastrointestinal, Liver, and Pancreatic Diseases 189
David Stump, MD

Clinical Syndromes 189 / Gastrointestinal Bleeding 189 / Abdominal Pain 195 / Dysphagia and Odynophagia 197 / Nausea and Vomiting 199 / Malabsorption Syndromes 202 / Diarrhea 205 / Constipation and Fecal Impaction 209 / Irritable Bowel Syndrome 210 / Intestinal Obstruction 212 / Jaundice 214 / Esophageal Diseases 217 / Peptic Esophagitis 217 / Infectious Esophagitis 218 / Esophageal Spasm 219 / Esophageal Achalasia 220 / Peptic Ulcer Disease 220 / Crohn's Disease 226 / Ulcerative Colitis 228 / Anorectal Disorders 230 / Hemorrhoids 231 / Anal Fissure 231 / Pruritus Ani 232 / Liver Disease 232 / Viral Hepatitis 232 / Alcoholic Liver Disease 237 / Cirrhosis and Liver Failure 238 / Acute or Chronic Hepatic Injury 246 / Miscellaneous Causes of Cirrhosis 247 / Pancreatic Disease 248 / Acute Pancreatitis 248 / Chronic

Pancreatitis 251 / Biliary Tract Disease 252 / Asymptomatic Gallstones 252 / Chronic Cholecystitis 252 / Acute Cholecystitis 253 / Ascending Cholangitis 253

7. Nutritional Assessment and Therapy 255

Eleanor A. Young, PhD, RD/LD, and
Elliot Weser, MD, FACP

Nutritional Assessment 255 / Anthropometric Assessment 255 / Laboratory Assessment 255 / Clinical Assessment 256 / Dietary Assessment 256 / Recommended Dietary Allowances (RDA) 257 / Calculation of Nutritional Requirements 261 / Total Energy (Calorie) Requirements (TER) 261 / Protein Requirements 262 / Lipid Requirements 262 / Carbohydrate Requirements 262 / Vitamins and Minerals 262 / Nitrogen: Calorie Ratio 263 / Nutritional Therapy 263 / Selection of Type of Nutritional Therapy 263 / Specific Types of Nutritional Therapy 264

8. Infectious Diseases 276

Jean A. Smith, MD

General Approach to the Patient 276 / Clinical Presentation 276 / Diagnostic Evaluation of the Febrile Patient 276 / Principles of Selection of Antimicrobial Agents 277 / Specific Antibacterial Agents 278 / Penicillins 278 / Cephalosporins 286 / Aminoglycosides 288 / Tetracyclines 289 / Erythromycin 290 / Clindamycin 290 / Metronidazole 290 / Chloramphenicol 291 / Sulfonamides 291 / Trimethoprim 291 / Trimethoprim and Sulfamethoxazole (TMP-SMZ, Co-Trimoxazole) 292 / Vancomycin 292 / Fluoroquinolones 293 / Systemic Antifungal Agents 293 / Amphotericin B 293 / Flucytosine 294 / Ketoconazole 294 / Pentamidine 295 / Bacterial and Viral Infections 295 / Bacteremic Shock 295 / Tonsillopharyngitis 296 / Acute Sinusitis 298 / Chronic Sinusitis 298 / Pneumonia 299 / Endocarditis 307 / Meningitis 310 / Brain Abscess 313 / Viral Encephalitis 313 / Herpes Zoster 313 / Gastrointestinal Infections 314 / Osteomyelitis 317 / Urinary Tract Infections (UTI) 318 / Sexually Transmitted Diseases (STD) 321 / Acquired Immunodeficiency Syndrome (AIDS) 327 / Tetanus 333 / Botulism 335 / Tuberculosis 336 / Infection With Mycobacteria Other than Mycobacterium Tuberculosis 338 / Fungal Infections 338 / Histoplasmosis 338 / Coccidioidomycosis 339 / Blastomycosis 340 / Aspergillosis 340 / Candidiasis 341 / Cryptococcosis 341 / Protozoal Infections 346 / Malaria 346

9. Rheumatologic and Musculoskeletal Diseases 348

I. Jon Russell, MD, PhD

General Approach to Clinical Assessment 348 / Infectious Arthritis 352 / Bacterial Joint Infections 352 / Lyme Arthritis (Lyme Disease) 353 / Viral Joint Infections 356 / Reactive Arthritis 356 / Acute Rheumatic Fever 356 / Other Reactive Disorders 359 / Crystalline Arthritis 359 / Gouty

Arthritis 359 / Pseudogout 361 / Hydroxyapatite-Induced Arthritic Syndromes 362 / Autoimmune Disorders 362 / Rheumatoid Arthritis 363 / Associated Disorders and Their Management 366 / Systemic Lupus Erythematosus (SLE) 368 / Progressive Systemic Sclerosis (Scleroderma) 372 / Eosinophilic Fasciitis 374 / Polymyositis-Dermatomyositis 374 / Polymyalgia Rheumatica 375 / Noninflammatory Arthritis 376 / Osteoarthritis (Degenerative Joint Disease) 376 / Primary (Familial) Osteoarthritis 378 / Secondary Osteoarthritis 378 / Erosive Osteoarthritis 378 / Diffuse Idiopathic Skeletal Hyperostosis (DISH) 378 / Seronegative Spondyloarthropathy 378 / Ankylosing Spondylitis 379 / Reiter's Syndrome 380 / Psoriatic Arthritis 381 / Arthritis of Inflammatory Bowel Disease 381 / Vascular Disorders 381 / Raynaud's Phenomenon 381 / Vasculitic Syndrome 382 / Periarthritic Pain Syndromes 387 / Bursitis 388 / Tendinitis 388 / Enthesopathy 388 / Entrapment Syndromes 389 / Referred Pain 390 / Fibrositis Syndrome (Fibromyalgia) 390

10. Skin Diseases 391

Bonnie B. Furrer, MD, and
Richard L. De Villez, MD

General Principles of Management of Skin Lesions 392 / Diagnostic Procedures for Evaluation of Skin Lesions 394 / Specific Dermatologic Diseases and Treatment 395 / Red Lesions With Scales, Generalized 395 / Red Lesions With Scales, Localized 396 / Red Lesions Without Scales, Generalized 399 / Red Lesions Without Scales, Localized 401 / Fluid-Filled Vesicles With Clear Fluid, Generalized 402 / Fluid-Filled Vesicles With Clear Fluid, Localized 405 / Fluid-Filled Vesicles, Purulent Material 406 / Miscellaneous Common Skin Disorders 408 /

11. Hematologic Disorders 412

Shirley P. Levine, MD

The Anemias 412 / History 412 / Physical Examination 412 / Initial Studies 413 / Anemias Due to Inadequate Production of Red Blood Cells 414 / Iron Deficiency Anemia 414 / Megaloblastic Anemias 415 / Aplastic Anemia 416 / Sideroblastic Anemia 418 / Anemia of Chronic Disease 418 / Anemia of Renal Failure 419 / Anemia of Pregnancy 419 / Anemias Due to Increased Destruction of Red Blood Cells 419 / Intrinsic Red Blood Cell Abnormalities 420 / Extrinsic Red Blood Cell Abnormalities 420 / Abnormalities in Hemoglobin and Globin Synthesis 422 / Bleeding Disorders 424 / General Laboratory Screening for Bleeding Disorders 424 / Quantitative Platelet Disorders 425 / Qualitative Platelet Disorders 427 / Coagulation Factor Deficiencies 428 / Thrombosis and Anticoagulant or Thrombolytic Therapy 431 / Arterial Thrombosis 431 / Venous Thrombosis 432 / Hypercoagulable States 434 / Transfusion Therapy 435 / Transfusion of Red Blood Cells 435 / Granulocyte Transfusions 436 / Platelet Transfusions 437 / Plasma Product Transfusion 437 / Benign Disorders of White Blood Cells 437 / Neutropenia 437 /

Neutrophilia 440 / *Myeloproliferative Disorders* 440 / *Polycythemia Vera* 440 / *Chronic Granulocytic Myelogenous Leukemia* 441 / *Agnogenic Myeloid Metaplasia or Myelofibrosis* 442 / *Primary Thrombocythemia* 442 / *Lymphoproliferative Disorders* 443 / *Chronic Lymphocytic Leukemia* 443 / *Multiple Myeloma* 444 / *Acute Leukemias* 445 / *Acute Nonlymphocytic Leukemia* 445 / *Acute Lymphocytic Leukemia* 446 / *Hodgkin's Disease and Non-Hodgkin Lymphomas* 446 / *Hodgkin's Disease* 446 / *Non-Hodgkin Lymphomas* 448

12. Oncology 450

Geoffrey R. Weiss, MD

General Approach to the Cancer Patient 451 / *Screening of Asymptomatic Patients* 451 / *Diagnosis* 452 / *Staging of Cancer* 452 / *Treatment Considerations* 453 / *Cancer Treatment Options* 454 / *Specific Approach to Cancer Management* 466 / *Breast Cancer* 467 / *Management of Complications of Cancer and Its Treatment* 471 / *Pain* 471 / *Nausea and Vomiting* 472 / *Granulocytopenia* 473 / *Neurologic Emergencies* 476 / *Superior Vena Caval Obstruction* 478 / *Malignant Effusions* 479 / *Chemotherapy Extravasation* 481 / *Metabolic Disorders* 482 / *Leukostasis and Hyperviscosity* 485 /

13. Endocrine Disorders 487

Michael S. Katz, MD, and

James F. Dunn, MD

Anterior Pituitary Disorders 487 / *Basic Considerations* 487 / *Pituitary Adenomas* 487 / *Hypersecretion Syndromes Associated With Pituitary Adenomas* 489 / *Hypopituitarism* 490 / *Posterior Pituitary Disorders* 491 / *Basic Considerations* 491 / *Diabetes Insipidus* 492 / *Adrenal Cortex* 493 / *Basic Considerations* 493 / *Primary Adrenal Insufficiency (Addison's Disease)* 494 / *Secondary Adrenal Insufficiency* 496 / *Congenital Adrenal Hyperplasia* 497 / *Hypercortisolism* 497 / *Primary Aldosteronism* 499 / *Thyroid Disorders* 499 / *Basic Considerations* 499 / *Hyperthyroidism (Thyrotoxicosis)* 500 / *Hypothyroidism* 503 / *Myxedema Coma* 505 / *Solitary Thyroid Nodule* 505 / *Asymptomatic Goiter* 506

14. Metabolic Disorders 507

A. John Yates, MD, and

Ralph A. DeFronzo, MD

Diabetes Mellitus 507 / *Diabetic Ketoacidosis* 519 / *Hyperosmolar Nonketotic Coma* 523 / *Chronic Complications of Diabetes Mellitus* 524 / *Hypoglycemia* 527 / *Fasting Hypoglycemia* 528 / *Postprandial Hypoglycemia* 529 / *Hyperlipidemia* 529 / *Disorders of Bone and Mineral Metabolism* 536 / *Hypercalcemia* 536 / *Hypocalcemia* 539 / *Hypophosphatemia* 540 / *Osteomalacia and Rickets* 541 / *Osteoporosis* 542 / *Renal Osteodystrophy* 543 / *Paget's Disease of Bone* 544 /

15. Neurologic Diseases	547
<i>David G. Sherman, MD</i>	
Coma 547 / Seizures 550 / Delirium and Dementia 553 /	
Headache 556 / Vertigo and Dizziness 558 / Degenerative	
Diseases 560 / Cerebrovascular Disease 563 / Myasthenia	
Gravis 567 / Multiple Sclerosis 568 / Peripheral	
Neuropathies 570 / Diabetic Neuropathy 570 / Alcohol	
Withdrawal Syndromes 573	
16. Emergencies	575
<i>Jonathan A. Leighton, MD, and</i>	
<i>Knox H. Todd, MD</i>	
Emergencies Discussed in Other Chapters 575 /	
Cardiopulmonary Arrest 575 / Upper Airway Obstruction 579	
/ Epistaxis 581 / Shock 582 / Anaphylactic Shock 585 /	
Poisoning and Overdose 588 / Ophthalmologic Problems 600	
/ Hypothermia 603 / Heat Illness 606 / Near-Drowning 608	
Appendix A. Hospital Orders	611
<i>Valerie A. Lawrence, MD, and</i>	
<i>Thomas C. Hardin, PharmD, FCCP</i>	
Appendix B. Drug Dosages for Patients with Renal Failure	613
<i>Claudia E. Hura, MD</i>	
Index	633

1 General Aspects of Drug Therapy

Valerie A. Lawrence, MD, and Thomas C. Hardin, PharmD, FCCP

BASIC PRINCIPLES OF DRUG THERAPY

- I. **Know a few drugs well**—sites of action, metabolism, routes of excretion, adverse effects, clinical and laboratory monitoring parameters. A limited repertoire with sufficient depth of knowledge and experience will ensure safer and more effective drug therapy than a wide-ranging but superficial one. If a new drug offers no advantage over an old one, prescribe the old drug, with which there is more experience and documented safety and which is probably less expensive as well.
- II. **Administer drugs only upon clear indications.** Do not prescribe drugs just to satisfy patients' expectations.
- III. **Dosage and monitoring**
 - A. Individualize the dosage according to age, weight, and renal, cardiac, and hepatic function.
 - B. Decide how the patient will be monitored for drug efficacy and toxicity.
 - C. Review medication orders regularly, and discontinue unnecessary drugs. Always consider whether symptoms, signs, or laboratory abnormalities might be drug-related. The frequency of adverse drug reactions is directly proportionate to the number of drugs prescribed. As many as 20% of patients have undesirable drug reactions during hospitalization.
- IV. **Give patients specific oral and written instructions** about medications. Remember that while you speak 2 "languages" (medical and lay), most patients speak only one.

PHARMACOKINETIC MONITORING

Pharmacokinetic monitoring is a means of individualizing drug therapy to maximize efficacy and minimize toxicity. Serum drug levels are helpful but are not a substitute for clinical monitoring. Monitoring of serum drug levels is most useful for drugs whose efficacy is not easily assessed by observation of clinical results or whose toxicity might be reduced with careful dosage titration.

- I. **Interpreting drug levels.** For house officers, the most common dilemmas in interpreting drug levels are uncertainties about missed doses and the timing of sample collection. Ideally, samples should be drawn when drug concentrations are at a steady state. If samples are drawn during the drug's distribution phase, the report will overestimate the drug concentration at the site of action.
- II. **Therapeutic drug levels.** See Table 1-1.

DRUG INTERACTION

A drug interaction is a pharmacologic response—usually but not invariably an adverse response—that cannot be explained by the action of a single drug but is

TABLE 1-1. THERAPEUTIC DRUG LEVELS

Drug	Therapeutic Range	When to Draw Level
Theophylline (many)	10–20 µg/mL	Before dose
Digoxin (Lanoxin)	0.8–2 ng/mL	Before dose (AM lab)
Quinidine (many)	2–5 µg/mL	Immediately before dose
Procainamide (Pronestyl)	4–8 µg/mL	Before dose
N-Acetylprocainamide (NAPA)	5–20 µg/mL	Before dose
Lidocaine (Xylocaine)	1–5 µg/mL	3 and 9 hours postinfusion
Phenytoin (Dilantin)	10–20 µg/mL	Before dose (AM lab)
Carbamazepine (Tegretol)	6–10 µg/mL	Before dose (AM lab)
Phenobarbital (many)	15–40 µg/mL	Before dose (AM lab)
Valproic acid (Depakene, Myproic Acid)	50–100 µg/mL	Before dose (AM lab)
Gentamicin (many)	Peak: 5–10 µg/mL Trough: < 2 µg/mL	30 minutes postinfusion Immediately before dose
Tobramycin (Nebcin)	Peak: 5–10 µg/mL Trough: < 2 µg/mL	Same as for gentamicin
Amikacin (Amikin)	Peak: 15–25 µg/mL Trough: < 10 µg/mL	Same as for gentamicin
Vancomycin (Vancocin, Vancoled)	Peak: 25–40 µg/mL Trough: 5–10 µg/mL	1 hour postinfusion Immediately before dose
Lithium (many)	0.7–1.5 meq/L	8–12 hours after dose
Salicylate	15–30 mg/dL	Random collection acceptable

due to 2 or more drugs acting simultaneously. Beneficial interactions occur when penicillin is given with probenecid, heparin with protamine, opiates with naloxone, or aminoglycosides with antipseudomonal penicillin. Examples of adverse drug interactions are given in Table 1–2. Always be aware that symptoms, signs, or laboratory abnormalities may be drug-related, and obtain detailed drug histories for both prescription and over-the-counter medications. Elderly persons have increased central nervous system and cardiac sensitivity to many drugs, and they frequently take multiple medications.

DRUG THERAPY AND RENAL FUNCTION

- I. **Drug clearance and dosage adjustment.** The clearance of many commonly prescribed drugs is reduced in renal insufficiency, and adjustments both in the amount of drug and frequency of administration are often necessary. (See Appendix B, p 567.) These changes in dosing are based on the creatinine clearance. In any situation of reduced renal function, the creatinine clearance can be estimated by the following equation:

$$C_{cr} = \frac{(140 - \text{age}) \times \text{kg}}{\text{Serum creatinine} \times 72} \quad \left(\begin{array}{l} \text{For women,} \\ \text{multiply by 0.85.} \end{array} \right)$$

- II. **Dialysis and drug clearance.** Important factors in drug clearance by hemodialysis include molecular weight, solubility, and protein binding. For a given dialysis membrane, clearance falls as molecular weight increases; drugs with molecular weights greater than 500 are usually not effectively removed by dialysis. Drugs insoluble in water are not soluble in the aqueous dialysate. Because effective dialysis is driven by the concentration gradient of free solute between plasma and dialysate, dialysis clearance falls as the fraction bound to protein increases. Table 1–3 shows the extent to which several commonly used drugs are dialyzable. (See also Appendix B, p 567.)

TABLE 1-2. DRUG INTERACTIONS
(NOTE: DRUGS AND DRUG CLASSES ARE ARRANGED ALPHABETICALLY. SCAN COLUMN A. IF DRUG IS NOT FOUND, SCAN COLUMN B.)

Interacting Drug or Drug Class (A)	Interacting Drug or Drug Class (B)	Mechanism*	Clinical Effect
Allopurinol	Azathioprine	3	Increased blood levels of 6-mercaptopurine (active metabolite of azathioprine).
Antacids (in general)	Cimetidine, iron preparations, isoniazid, penicillamine, phenothiazines, ranitidine, tetracycline	1, 4	May result in decreased serum levels of B.
Antacids (in general)	Salicylates	6	May see decrease in serum salicylate levels due to alkalization of the urine.
Anticonvulsants (phenytoin, phenobarbital, carbamazepine)	Antiarrhythmics; oral anticoagulants, anticonvulsants, beta-blockers, oral contraceptives, corticosteroids, narcotics, theophylline	2	May result in decreased serum levels of B; potential for subtherapeutic effect. For example, decreased prothrombin time in patients receiving warfarin.
Beta-blockers	Antidiabetic agents	9	Beta-blocking agents can delay glucose recovery from insulin-induced hypoglycemia and may inhibit cardiac stimulatory response to hypoglycemia.
Cholestyramine	Acetaminophen, digitalis glycosides, hydrocortisone, thyroid hormones, warfarin	1	May result in decreased serum levels of B; potential for subtherapeutic effect. For example, patient may develop worsening heart failure if digoxin and cholestyramine are given concurrently.
Cimetidine	Oral anticoagulants, beta-blockers, lidocaine, phenytoin, quinidine, theophylline, verapamil	3	May result in increased serum levels of B; increased risk of toxicity. For example, patient may experience arrhythmias due to theophylline toxicity.
Cimetidine	Procainamide	7	Increased procainamide and N-acetylprocainamide serum levels; increased risk of toxicity.
Ciprofloxacin	Theophylline	3	May increase theophylline level and potential toxicity.
Digoxin	Cholestyramine, diuretics, amphotericin B, quinidine, verapamil		Please refer to interacting drugs where listed in column A.
Diuretics; amphotericin B	Digitalis glycosides	8	Hypokalemia induced by A may enhance development of digitalis toxicity.
Diuretics, loop (eg, furosemide)	Aminoglycosides	9	Potential of ototoxicity of either compound.
Erythromycin	Theophylline	3	May result in increased serum theophylline levels; dose- and duration-dependent.

(continued)